On April 1, 2026, the U.S. Food and Drug Administration (FDA) announced the approval of Foundayo (orforglipron), Eli Lilly's novel daily oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults. This approval marks a significant development in the treatment landscape for obesity, offering a convenient oral formulation as an alternative to the currently available injectable GLP-1 medications.
Foundayo's approval is based on data demonstrating its efficacy in reducing body weight in clinical trials. Unlike some other GLP-1 agonists, Foundayo is designed to be taken once daily by mouth, potentially improving patient adherence and accessibility. A notable feature of Foundayo is its reduced restrictions on food and water intake around dosing, which has been a common challenge with other oral GLP-1 medications requiring specific timing relative to meals and liquids.
The development of Foundayo addresses a key unmet need for patients seeking non-injectable options for weight management. The FDA's decision underscores the agency's commitment to providing diverse treatment avenues for chronic conditions like obesity, which affects millions of Americans. This approval was granted under the National Priority Voucher Program, indicating the drug's importance in public health.
Eli Lilly stated that Foundayo will be available by prescription later in 2026. Healthcare providers will be able to prescribe Foundayo for adults with obesity (defined as a body mass index (BMI) of 30 kg/m² or greater) or overweight (BMI of 27 kg/m² or greater) with at least one weight-related comorbidity, such as hypertension or type 2 diabetes. Patients are advised to use Foundayo in conjunction with a reduced-calorie diet and increased physical activity.